Summary of studies
| . | CALGB 10503 (N = 546) . | CALGB 10603 (N = 717) . | CALGB 10801 (N = 61) . | CALGB 11001 (N = 54) . | CALGB 10201 (N = 506) . |
|---|---|---|---|---|---|
| Age, y | |||||
| Median | 48 | 47 | 50 | 67 | 69 |
| Range | 17-60 | 18-60 | 19-85 | 60-82 | 60-88* |
| Sex | |||||
| Male | 298 (55) | 318 (44) | 31 (51) | 30 (56) | 307 (61) |
| Female | 248 (45) | 399 (56) | 30 (49) | 24 (44) | 199 (39) |
| Performance score | |||||
| 0 | 187 (34) | 306 (43) | 28 (46) | 23 (43) | 151 (30) |
| 1 | 310 (57) | 327 (46) | 25 (41) | 27 (50) | 280 (55) |
| ≥2 | 48 (9) | 84 (12) | 7 (11) | 4 (7) | 75 (15) |
| Deaths | 307 (56) | 357 (50) | 13 (21) | 38 (70) | 464 (92) |
| Follow-up, mo† | |||||
| Median | 60 | 58 | 34 | 28 | 100 |
| IQR | 51-65 | 47-67 | 26-41 | 18-32 | 87-105 |
| EFS events | 395 (72) | 541 (75) | 22 (36) | 43 (80) | 476 (94) |
| No CR1‡ | 175 (32) | 317 (44) | 8 (13) | 17 (31) | 273 (54) |
| Early death | 28 (5) | 27 (4) | 3 (5) | 4 (7) | 77 (15) |
| Early progression | 3 (1) | 1 (0) | 0 (0) | 1 (2) | 16 (3) |
| Induction failure | 144 (26) | 289 (40) | 5 (8) | 12 (22) | 180 (36) |
| Relapse after CR1§ | 181 (33) | 182 (25) | 13 (21) | 20 (37) | 164 (32) |
| Death without relapse in CR1§ | 39 (7) | 42 (6) | 1 (2) | 6 (11) | 39 (8) |
| . | CALGB 10503 (N = 546) . | CALGB 10603 (N = 717) . | CALGB 10801 (N = 61) . | CALGB 11001 (N = 54) . | CALGB 10201 (N = 506) . |
|---|---|---|---|---|---|
| Age, y | |||||
| Median | 48 | 47 | 50 | 67 | 69 |
| Range | 17-60 | 18-60 | 19-85 | 60-82 | 60-88* |
| Sex | |||||
| Male | 298 (55) | 318 (44) | 31 (51) | 30 (56) | 307 (61) |
| Female | 248 (45) | 399 (56) | 30 (49) | 24 (44) | 199 (39) |
| Performance score | |||||
| 0 | 187 (34) | 306 (43) | 28 (46) | 23 (43) | 151 (30) |
| 1 | 310 (57) | 327 (46) | 25 (41) | 27 (50) | 280 (55) |
| ≥2 | 48 (9) | 84 (12) | 7 (11) | 4 (7) | 75 (15) |
| Deaths | 307 (56) | 357 (50) | 13 (21) | 38 (70) | 464 (92) |
| Follow-up, mo† | |||||
| Median | 60 | 58 | 34 | 28 | 100 |
| IQR | 51-65 | 47-67 | 26-41 | 18-32 | 87-105 |
| EFS events | 395 (72) | 541 (75) | 22 (36) | 43 (80) | 476 (94) |
| No CR1‡ | 175 (32) | 317 (44) | 8 (13) | 17 (31) | 273 (54) |
| Early death | 28 (5) | 27 (4) | 3 (5) | 4 (7) | 77 (15) |
| Early progression | 3 (1) | 1 (0) | 0 (0) | 1 (2) | 16 (3) |
| Induction failure | 144 (26) | 289 (40) | 5 (8) | 12 (22) | 180 (36) |
| Relapse after CR1§ | 181 (33) | 182 (25) | 13 (21) | 20 (37) | 164 (32) |
| Death without relapse in CR1§ | 39 (7) | 42 (6) | 1 (2) | 6 (11) | 39 (8) |
All data are n (%) unless otherwise noted.
IQR, interquartile range.
One ineligible patient was age 48 y and excluded from the analysis; all other eligible patients were age ≥60 y in CALGB 10201.
Defined as lower to upper quantile.
No CR1 indicates induction failure by 60 d after registration/randomization.
CR1 indicates CR during induction (by 60 d after registration/randomization).